Quality of Patient-reported Outcome Reporting According to the CONSORT Statement in Randomized Controlled Trials with Glioblastoma Patients

Overview

Journal Neurooncol Pract

Publisher Oxford University Press

Date 2021 Apr 26

PMID 33898048

Citations 3

Authors

Louis Garnier

Emilie Charton

Antoine Falcoz

Sophie Paget-Bailly

Dewi Vernerey

Marine Jary

Francois Ducray

Elsa Curtit

Affiliations

Soon will be listed here.

Abstract

Background: Randomized controlled trials (RCTs) represent the best evidence in oncology research. Glioblastoma is the most frequent and deadly primary brain tumor, affecting health-related quality of life. An important end point is patient-reported outcomes (PROs). There are no data regarding how well publications of glioblastoma RCTs report PROs. A specific PRO extension of the Consolidated Standards of Reporting Trials (CONSORT) statement was created to improve the quality of reporting. The aim of this study was to evaluate adherence to the CONSORT-PRO statement in reporting RCTs addressing the treatment of patients with glioblastoma. PRO analysis methodology was explored and criteria associated with higher quality of reporting were investigated.

Methods: From PubMed/MEDLINE and the Cochrane Library databases, all phase 2 and 3 RCTs related to glioblastoma published between 1995 and 2018 were reviewed according to the CONSORT-PRO statements. An overall quality score on a 0 to 100 scale was defined based on these criteria and factors associated with this score were identified.

Results: Forty-four RCTs were identified as relevant according to predefined criteria. The median overall quality score was 26. No difference was observed regarding reporting quality over the years. CONSORT-PRO items concerning data collection and analysis were poorly reported. Thirty-four trials (77%) used longitudinal data. The most frequent statistical method for PROs analysis was the mean change from baseline (63%). Factors associated with improved overall quality score were the presence of a secondary publication dedicated to PROs results, the statement of any targeted dimensions, and when trials reported results using multiple methods.

Conclusion: Despite the importance of measuring PROs in patients with glioblastoma, employment of the CONSORT-PRO statement is poor in RCTs.

Citing Articles

The reporting quality of randomized controlled trials in pharmacotherapy for pituitary adenomas.

Yan H, Wang D, Zhao Y, Miao J, Wang Z Medicine (Baltimore). 2024; 103(11):e37518.

PMID: 38489678 PMC: 10939664. DOI: 10.1097/MD.0000000000037518.

Development of a core outcome set for use in adult primary glioma phase III interventional trials: A mixed methods study.

Retzer A, Baddeley E, Sivell S, Scott H, Nelson A, Bulbeck H Neurooncol Adv. 2023; 5(1):vdad096.

PMID: 37719788 PMC: 10503650. DOI: 10.1093/noajnl/vdad096.

Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects.

Pineda E, Domenech M, Hernandez A, Comas S, Balana C Onco Targets Ther. 2023; 16:71-86.

PMID: 36721854 PMC: 9884437. DOI: 10.2147/OTT.S366371.

References

Turner L, Shamseer L, Altman D, Schulz K, Moher D . Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev. 2012; 1:60. PMC: 3564748. DOI: 10.1186/2046-4053-1-60. View

Osoba D, Rodrigues G, Myles J, Zee B, Pater J . Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16(1):139-44. DOI: 10.1200/JCO.1998.16.1.139. View

Brundage M, Bass B, Davidson J, Queenan J, Bezjak A, Ringash J . Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res. 2010; 20(5):653-64. DOI: 10.1007/s11136-010-9793-3. View

Bylicki O, Gan H, Joly F, Maillet D, You B, Peron J . Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy. Ann Oncol. 2014; 26(1):231-237. DOI: 10.1093/annonc/mdu489. View

Peron J, Pond G, Gan H, Chen E, Almufti R, Maillet D . Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst. 2012; 104(13):982-9. DOI: 10.1093/jnci/djs259. View

Beitz J, Gnecco C, Justice R . Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr. 1996; (20):7-9. View

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

Lai R, Chu R, Fraumeni M, Thabane L . Quality of randomized controlled trials reporting in the primary treatment of brain tumors. J Clin Oncol. 2006; 24(7):1136-44. DOI: 10.1200/JCO.2005.03.1179. View

Concato J, Shah N, Horwitz R . Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000; 342(25):1887-92. PMC: 1557642. DOI: 10.1056/NEJM200006223422507. View

10.

Anota A, Barbieri A, Savina M, Pam A, Gourgou-Bourgade S, Bonnetain F . Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study. Health Qual Life Outcomes. 2015; 12:192. PMC: 4326524. DOI: 10.1186/s12955-014-0192-2. View

11.

Mercieca-Bebber R, Rouette J, Calvert M, King M, McLeod L, Holch P . Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension. Qual Life Res. 2017; 26(6):1427-1437. DOI: 10.1007/s11136-017-1508-6. View

12.

Dirven L, Reijneveld J, Taphoorn M . Health-related quality of life or quantity of life: a difficult trade-off in primary brain tumors?. Semin Oncol. 2014; 41(4):541-552. DOI: 10.1053/j.seminoncol.2014.06.002. View

13.

Basch E . The missing voice of patients in drug-safety reporting. N Engl J Med. 2010; 362(10):865-9. PMC: 3031980. DOI: 10.1056/NEJMp0911494. View

14.

Mansouri A, Shin S, Cooper B, Srivastava A, Bhandari M, Kondziolka D . Randomized controlled trials and neuro-oncology: should alternative designs be considered?. J Neurooncol. 2015; 124(3):345-56. DOI: 10.1007/s11060-015-1870-6. View

15.

Coomans M, Dirven L, Aaronson N, Baumert B, van den Bent M, Bottomley A . The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. Eur J Cancer. 2019; 116:190-198. DOI: 10.1016/j.ejca.2019.05.012. View

16.

Fiteni F, Anota A, Westeel V, Bonnetain F . [Health-related quality of life in phase III cancer clinical trials: from questionnaire administration to statistical analysis]. Bull Cancer. 2015; 102(4):360-6. DOI: 10.1016/j.bulcan.2015.02.014. View

17.

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

18.

Dirven L, Aaronson N, Heimans J, Taphoorn M . Health-related quality of life in high-grade glioma patients. Chin J Cancer. 2014; 33(1):40-5. PMC: 3905089. DOI: 10.5732/cjc.013.10214. View

19.

Coens C, Pe M, Dueck A, Sloan J, Basch E, Calvert M . International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncol. 2020; 21(2):e83-e96. DOI: 10.1016/S1470-2045(19)30790-9. View

20.

Sagberg L, Solheim O, Jakola A . Quality of survival the 1st year with glioblastoma: a longitudinal study of patient-reported quality of life. J Neurosurg. 2015; 124(4):989-97. DOI: 10.3171/2015.4.JNS15194. View